Literature DB >> 9211659

Absorption, metabolism and excretion after oral administration of a new Ca antagonist, 14C-benidipine hydrochloride to man.

H Kobayashi1, S Kobayashi, P D Dalrymple, S G Wood, L F Chasseaud.   

Abstract

1. In healthy male volunteers, the absorption, metabolite profiles and excretion of 14C-benidipine hydrochloride, a new Ca antagonist, were investigated after oral administration at a dose of 8 mg. 2. 14C-benidipine hydrochloride was rapidly absorbed, and the plasma concentration of radioactivity and unchanged drug reached a maximum of 71.2 ng eq./ml at 1.1 h and 2.56 ng/ml at 0.6 h respectively, and then declined bi-exponentially. The half-life in the elimination phase was 14.7 and 5.3 h respectively, AUC of unchanged drug was low, about 1% of that of radioactivity. 3. Five days after administration, 36.4% of the administered radioactivity was excreted in urine and 58.9% in faeces. 4. The metabolite profiles in plasma, urine and faeces were analysed by hplc. At 1 h after administration the predominant metabolites in plasma were M9 and M2, which accounted for 13.8 and 8.2% of the radioactivity respectively, whereas unchanged drug represented 1.2%. Predominant metabolites in urine 12 h after administration were M3 and M8, which accounted for 2.22 and 2.21% of the administered radioactivity respectively. Metabolites excreted in faeces 120 h after administration were very complex and poorly separated by hplc and could not be characterized: unchanged drug was not detected in the faeces.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9211659     DOI: 10.1080/004982597240370

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  3 in total

1.  Urinary excretion of the 1,4-dihydropyridine calcium antagonist VULM 993 and its metabolites in the rat.

Authors:  M Stefek; V Faberova; S Musil; I Kakalik
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2001 Oct-Dec       Impact factor: 2.441

2.  Effect of rifampin on enantioselective disposition and anti-hypertensive effect of benidipine.

Authors:  Yu Eun Sunwoo; Phuong Thi Thu Nguyen; Chin May Chien; Ji Young Ryu; Jihong Shon; Jae-Gook Shin
Journal:  Br J Clin Pharmacol       Date:  2019-01-30       Impact factor: 4.335

3.  Therapeutic Effect of Benidipine on Medication-Related Osteonecrosis of the Jaw.

Authors:  Ken Matsunaka; Mikio Imai; Koma Sanda; Noriyuki Yasunami; Akihiro Furuhashi; Ikiru Atsuta; Hiroko Wada; Yasunori Ayukawa
Journal:  Pharmaceuticals (Basel)       Date:  2022-08-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.